IN THE UNITED STATES DISTRICT COURT FOR THE NORTHEN DISTRCT OF ILLINOIS EASTERN DIVISION

PSN ILLINOIS, LLC, an Illinois corporation,) Case No. 07 C 7190
1	Plaintiff,)) Judge Hibbler
vs.)) Magistrate Judge Valdex
Abcam, Inc.; Abgent, Inc.; Affinity Bioreagents, Inc.; Discoverx Corporation;)))
Exalpha Biologicals, Inc.;		í)
Genetex, Inc.; LifeSpan Bios Multispan, Inc.; and Novus Biologicals, Inc.	ciences, Inc.;))
,		,)
	Defendants.)

CONSENT JUDGMENT ORDER AS TO DEFENDANT ABGENT

This action has come before the Court upon the pleadings and proceedings of record, and it has been represented to the Court that the parties, plaintiff PSN Illinois, LLC ("PSN") and defendant Abgent, Inc. ("Abgent"), collectively "the Parties," have agreed to a compromise and settlement of this action and have entered into a Confidential Settlement And License Agreement dated March 24, 2008 ("the Settlement Agreement") wherein Abgent has agreed to the entry of this judgment;

WHEREFORE, with the consent of the Parties, through their undersigned attorneys, and with the approval of this Court, it is hereby finally ORDERED, ADJUDGED AND DECREED as follows:

- 1. The Court has jurisdiction over the parties and the subject matter of this action.
 - 2. PSN owns and has standing to sue for infringement of United

States Patent No. 5,856,443, entitled "Molecular Cloning And Expression of G-Protein Coupled Receptors," issued on Jan. 5, 1999, and United States Patent No. 6,518,414B1, entitled "Molecular Cloning And Expression of G-Protein Coupled Receptors," issued on Feb. 11, 2003 ("PSN's Patents").

- 3. Each of the claims of PSN's Patents are valid and enforceable.
- 4. PSN's Patents have been infringed by Abgent through its distribution and offer for sale of products and services utilizing Sphingosine 1-Phosphate Receptor 2/ aka Edg 5/ aka PH218 ("S1P2") that fall within the scope of claims of PSN's Patents, including at least the following Abgent products: S1P2 purified rabbit polyclonal antibody (Catalog # AP6141a); and S1P2 antibody (N-term) blocking peptide (Catalog # BP6141a) ("the infringing products").
- Abgent agrees to pay a fifteen percent (15%) royalty for past and future 5. sales of the infringing products, as further detailed in the parties' Settlement Agreement. No payment for or release of the infringing products as to their transaction or use by any third parties is provided here or in the parties' Settlement Agreement, and PSN is free to pursue its damages claim in this action against such third parties.
- Abgent agrees to and hereby waives and relinquishes the right to ever 6. contest the validity or enforceability of either of PSN Patents and any of their claims in their present form, whether such assertion of invalidity or unenforceability would be made in a court proceeding or Patent Office proceeding, and whether or not such assertion is made with respect to the infringing products in this action or with respect to any other products that may be made, used, sold and/or offered for sale by Abgent in the future.

- 7. All claims and defenses of each of the Parties are hereby dismissed with prejudice.
- 8. The parties shall each bear their own costs and attorney fees incurred in this action, and the Court shall retain jurisdiction to enforce the terms of this Consent Judgment Order and the corresponding Settlement Agreement between the parties concerning this action.

Dated: __3/26 2008

Honorable William J. Hibbler United States District Court Judge

Steven E. Comer

Morrison & Foerster LLP

12531 High Bluff Drive, Suite 100

San Diego, CA 92130 Tel: (858) 720-5117

Tel: (858) 720-5125

Attorneys for ABGENT, INC.

Michael P. Mazza

Michael P. Mazza, LLC

686 Crescent Blvd. Glen Ellyn, IL 60137

Tel: 630-858-5071 Fax: 630-282-7123

Attorneys for PSN ILLINOIS, LLC